Adverse reactions related to trastuzumab deruxtecan:a literature analysis
Objective To analyze the occurrence and clinical characteristics of adverse reactions(ADR)related to trastuzumab derux-tecan,and provide reference for rational drug use in clinical practice.Methods By retrieval in databases such as CNKI,Wanfang,VIP,Chaoxing,PubMed,and Embase,case reports of adverse reactions caused by trastuzumab deruxtecan were screened,and statisti-cal analysis was conducted on the general information,medication situation,and characteristics of adverse reactions of patients.Results According to the inclusion and exclusion criteria of literature,a total of 12 valid literature were screened out,involving 23 cases with an average age of 54.2 years(38～80 years).The primary diseases were mainly breast cancer,non-small cell lung cancer,and gastric adenocarcinoma with various site metastases.The average occurrence time of ADR caused by trastuzumab deruxtecan was 38 d(7 d to 4 months).ADR mainly affected the blood system(24.44%),systemic diseases(22.22%),and respiratory system(15.56%).After the occurrence of ADR,23 patients promptly stopped taking medication,21(91.30%)patients showed improvement in symptoms after receiving symptomatic treatment,and 2 patients died.Conclusions Before using trastuzumab deruxtecan for treatment,the patient's medication evaluation should be performed,and ADR monitoring should be emphasized.During the treatment period,a patient's lung and heart function indicators should be closely monitored.Once ADR occurs,timely intervention measures should be taken to ensure medication safety.
Antibodies,monoclonalTrastuzumab deruxtecanBreast cancerAdverse drug reactionLiterature analysis
万方数据
维普
